This compound was shown to induce cellular stress and apoptosis in acute myeloid leukemia (AML) cells and could reduce AML growth in vivo [117] (Table 4), suggesting that G2A may be a promising target for the treatment of acute myeloid leukemia. Here, GPR132 is linked to acute myeloid leukemia.